Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
NEW ORLEANS and CARLSBAD, Calif., November 06, 2008/PRNewswire-FirstCall/ Isis Pharmaceuticals, Inc. announces the following webcast:
What: Isis' cardiovascular program review of development and late-stage research candidates, including presentations from: -- Dr. Erik Stroes reporting top line data from an ongoing Phase 2 mipomersen liver imaging study -- Dr. Evan Stein providing an update on an open-label extension study of mipomersen in subjects with familial hypercholesterolemia When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m. PT/7:00 p.m. ET) Where: How: Live on the Internet. Simply log onto the website listed above. Contacts: Kristina Lemonidis Associate Director, Corporate Development Isis Pharmaceuticals, Inc. (760) 603-2490 Amy Blackley, Ph.D. Manager, Corporate Communications Isis Pharmaceuticals, Inc. (760) 603-2772
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide.
Posted: November 2008